Conventional re-irradiation for recurrent or second primary (RSP) head and neck cancer is associated with high treatment related morbidity with modest disease and survival outcomes. We performed a pooled analysis of patients receiving re-irradiation with IMRT (re-IMRT) with the hypothesis that disease and toxicity related outcomes would be more favorable than previous techniques. We also investigated the impact of dose, volume, and fractionation on these outcomes.